Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

PHASE4CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Vivax Malaria
Interventions
DRUG

Chloroquine sulfate

Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days

DRUG

DHA-PP

DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.

Trial Locations (1)

Unknown

Provincial Hospital, Banlung

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Institut Pasteur, Cambodia

OTHER

NCT02118090 - Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia: | Biotech Hunter | Biotech Hunter